Fact based stock research
Pfizer (NYSE:PFE)


Pfizer stock research in summary

pfizer.com


Pfizer shares have a SELL rating. While they are good value, they are riskily financed, and show below average growth. We recommend selling Pfizer shares.


Latest Obermatt Ranks


Country USA
Industry Pharmaceuticals
Index Dow Jones, S&P 500, D.J. US Pharmaceutical
Size class XX-Large

February 9, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: Pfizer

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
68
36
53
53
STOCK GROWTH RANKS
13
52
21
21
STOCK SAFETY RANKS
75
55
29
29
COMBINED STOCK RANKS
57
50
12
12

Last update of Combined Rank: 9-Feb-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Pfizer in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2015 2016 2017 2018
PRICE VS. REVENUES (P/S)
31
21
18
18
PRICE VS. PROFITS (P/E)
59
28
51
51
PRICE VS. CAPITAL (Market-to-Book)
48
39
41
41
DIVIDEND YIELD
88
88
92
92
CONSOLIDATED RANK: VALUE
68
36
53
53

Last update of Value Rank: 9-Feb-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Pfizer; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
25
59
7
7
PROFIT GROWTH
11
20
37
37
STOCK RETURNS
34
57
48
48
CONSOLIDATED RANK: GROWTH
13
52
21
21

Financial reporting date of Growth Rank: 1-Oct-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Pfizer.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
43
32
32
32
REFINANCING
35
35
LIQUIDITY
82
69
29
29
CONSOLIDATED RANK: SAFETY
75
55
29
29

Financial reporting date of Safety Rank: 31-Jan-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Pfizer and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Pfizer from February 9, 2018.